WU, W., CHEN, Y., TSAI, C., SHIH, J., CHIU, C., CHOU, K., . . . WHANG-PENG, J. (2012). Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. D.A. Spandidos.
Trích dẫn kiểu ChicagoWU, WEN-SHUO, et al. Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations. D.A. Spandidos, 2012.
Trích dẫn MLAWU, WEN-SHUO, et al. Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations. D.A. Spandidos, 2012.
Cảnh báo: Các trích dẫn này có thể không phải lúc nào cũng chính xác 100%.